and Medicare and Medigap coverage for Xarelto. It also looks at costs, including generic brand options. For Medicare to cover Xarelto, doctors must use it as approved by the FDA. Medicare coverage ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...

Xarelto, from Bayer and Johnson & Johnson ... But Entresto faces pricing challenges. Patents protecting the product expire in 2025 and 2026. Entresto was also selected as one of the first 10 ...

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...

Xarelto® (rivaroxaban tablets ... 11,576,894 Submission of Macleods ANDA to FDA was a technical act of patent infringement with respect to the ’894 patent. The claims of the ’894 patent ...

Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...